Abstract
A number of hepatic and extra-hepatic autoimmune disorders may complicate a percentage of patients with hepatitis C virus (HCV) infection that is both hepatotropic and lymphotropic agent; the resulting clinical phenotypes can be grouped into the so-called HCV syndrome. This latter includes various rheumatic disorders that are frequently characterized by clinical or serological overlap; thus, a correct patients’ classification is necessary prior to decide the therapy.
The management of these conditions is particularly difficult, given the coexistence of viral infection and immunological alterations. In this scenario, cryoglobulinemic vasculitis represents the prototype of HCV-related rheumatic disorders that can be treated at different levels by means of etiological (antivirals) and/or pathogenetic and/or symptomatic treatments (rituximab, cyclophosphamide, steroids, plasmapheresis, etc). In clinical practice, the therapeutic strategy should take into account the specific symptoms combination and the severity/activity of the disease, according to each patient’s conditions. This review focuses on the clinico-diagnostic assessments and therapeutical approaches of some rheumatic disorders complicating HCV infection, mainly arthritis, sicca syndrome, and osteosclerosis; while, cryoglobulinemic vasculitis is comprehensively examined in another article of the present issue.
Keywords: Hepatitis C virus, HCV, mixed cryoglobulinemia, vasculitis, arthritis, Sjögren’s syndrome, ostesclerosis, lymphoma, antiviral, rituximab.
Current Drug Targets
Title:HCV-Related Rheumatic Manifestations and Therapeutic Strategies
Volume: 18 Issue: 7
Author(s): Marco Sebastiani, Dilia Giuggioli, Michele Colaci, Poupak Fallahi, Laura Gragnani, Alessandro Antonelli, Anna Linda Zignego and Clodoveo Ferri*
Affiliation:
- Rheumatology Unit, Department of Internal Medicine, University of Modena and Reggio E., Policlinico di Modena, Via del Pozzo, 71, 41100 Modena,Italy
Keywords: Hepatitis C virus, HCV, mixed cryoglobulinemia, vasculitis, arthritis, Sjögren’s syndrome, ostesclerosis, lymphoma, antiviral, rituximab.
Abstract: A number of hepatic and extra-hepatic autoimmune disorders may complicate a percentage of patients with hepatitis C virus (HCV) infection that is both hepatotropic and lymphotropic agent; the resulting clinical phenotypes can be grouped into the so-called HCV syndrome. This latter includes various rheumatic disorders that are frequently characterized by clinical or serological overlap; thus, a correct patients’ classification is necessary prior to decide the therapy.
The management of these conditions is particularly difficult, given the coexistence of viral infection and immunological alterations. In this scenario, cryoglobulinemic vasculitis represents the prototype of HCV-related rheumatic disorders that can be treated at different levels by means of etiological (antivirals) and/or pathogenetic and/or symptomatic treatments (rituximab, cyclophosphamide, steroids, plasmapheresis, etc). In clinical practice, the therapeutic strategy should take into account the specific symptoms combination and the severity/activity of the disease, according to each patient’s conditions. This review focuses on the clinico-diagnostic assessments and therapeutical approaches of some rheumatic disorders complicating HCV infection, mainly arthritis, sicca syndrome, and osteosclerosis; while, cryoglobulinemic vasculitis is comprehensively examined in another article of the present issue.
Export Options
About this article
Cite this article as:
Sebastiani Marco, Giuggioli Dilia, Colaci Michele, Fallahi Poupak, Gragnani Laura, Antonelli Alessandro, Zignego Linda Anna and Ferri Clodoveo*, HCV-Related Rheumatic Manifestations and Therapeutic Strategies, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450116666150907103622
DOI https://dx.doi.org/10.2174/1389450116666150907103622 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of WNT in Rheumatoid Arthritis and its Therapeutic Implication
Mini-Reviews in Medicinal Chemistry PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Can Drug Effects Help Elucidate the Pathogenesis of SLE?
Current Rheumatology Reviews The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued) Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Past and Present Behçet’s Disease Animal Models
Current Drug Targets Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry New Method of Inhibition of Activity of Tumor Necrosis Factor Alpha In Patients with Psoriasis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The CX3C-Chemokine Fractalkine in Kidney Diseases
Mini-Reviews in Medicinal Chemistry Neurofibrillary Tangles and Senile Plaques in Alzheimers Brains are Associated with Reduced Capillary Expression of Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase
Current Neurovascular Research Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Rheumatic Manifestations Associated with Inflammatory Bowel Diseases
Current Rheumatology Reviews Leptin in Non-Autoimmune Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design The Phage Display Technique: Advantages and Recent Patents
Recent Patents on DNA & Gene Sequences Adrenal Insufficiency Caused by Locally Applied Glucocorticoids-Myth or Fact?
Current Medicinal Chemistry